Vaginal Antifungals Market is anticipated to reach US$ 1.76 Billion by 2033, at a CAGR of 4.5%

According to Future Market Insights’ most recent industry report, the global Vaginal Antifungals Market size is expected to reach US$ 1.14 Billion in 2023, with a CAGR of 4.5% over the forecast period, reaching US$ 1.76 Billion in 2033.

The global market for Vaginal Antifungals is expected to grow significantly over the forecast period. This is due to the expansion of innovative antifungal drug research as well as the global increase in healthcare costs. Furthermore, the growing prevalence of bacterial vaginosis is driving the market. It is the most common cause of vaginal discharge in women of reproductive age, which leads to fungal infections.

For Details on Vendors and Their Offerings – Request A Sample Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-17096

Rising trichomoniasis and candida cases are also boosting the market for Vaginal Antifungals. A compromised immune system and the use of oral contraceptives or hormone therapy that elevates oestrogen levels are the primary reasons of candida growth that leads to vaginal yeast infection.

Furthermore, firms are focusing on obtaining permission for novel products that can meet unmet needs and increase their market position. Furthermore, the increased need for better treatment choices is driving breakthroughs in R&D, new approvals, and drug launches, creating a profitable window for business expansion.

Key Takeaways:

• Polyenes are the dominant product segment, with a 49.0% market value share in 2022, owing to lower unfavourable effects and lower product costs.
• Due to the high preference of doctors and effective cure for the condition, the topical segment is expected to lead the mode of administration sector of the Vaginal Antifungals market with a projected market value share of roughly 73.1% in 2022.
• Bacterial Vaginosis leads the indication sector with a 44.9% market share, owing to its higher prevalence compared to other indications.
• Gynaecology clinics had a distribution channel share of roughly 41.4% in 2022, as the patient pool primarily consists of females who prefer to obtain consultation and treatment at Gynaecology centres.
• North America dominated the global market with significant contribution from U.S. region. US held a value share of around 27.0% in 2022 globally, due to rising prevalence of trichomoniasis in the region.

“Rising prevalence of severe vaginal infectious disorders, increasing rate of testing and launch of Vaginal Antifungals by players will boost the global market for Vaginal Antifungals,” says an analyst at Future Market Insights.

Our advisory services are aimed at helping you with specific, customized insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with you@ https://www.futuremarketinsights.com/ask-question/rep-gb-17096

Market Competition:

The market participants are concentrating on creating and introducing enhanced treatment drugs in order to increase the accuracy and efficiency of the operations and reduce adverse effect problems.

• Brexafemme, a high-class antifungal for the treatment of vulvovaginal candidiasis (VCC), will be commercialised and further developed by GSK plc and SCYNEXIS Inc. in 2023 under an exclusive licencing agreement. These drugs have also been approved by the FDA.

Key Players:

• Pfizer Inc.
• Bausch Health Companies Inc
• ANI Pharmaceuticals, Inc.
• Hikma Pharmaceuticals Plc
• Lupin Limited
• Mycovia Pharmaceuticals, Inc.
• Glenmark Pharmaceuticals Limited
• GSK plc.
• Others

What Does the Report Cover?

Future Market Insights offers a unique perspective and actionable insights on the Vaginal Antifungals market in its latest study, presenting a historical demand assessment of 2018 to 2022 and projections for 2023 to 2033. The global Vaginal Antifungals market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

Contact Sales for Further Assistance in Purchasing this Report@ https://www.futuremarketinsights.com/checkout/17096

Key Market Segments Covered:

By Product:

• Polyenes
• Azoles
• Allylamines
• Echinocandins
• Others

By Route of Administration:

• Oral
• Topical

By Indication:

• Bacterial Vaginosis
• Candidiasis
• Trichomoniasis
• Others

Distribution Channel:

• Hospital Pharmacies
• Supermarkets/hypermarkets
• Online Pharmacies
• Gynecology Clinics
• Others

About Future Market Insights, Inc.

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn | Twitter | Blogs